COVID-19 is an emerging, rapidly evolving situation.
- COVID Minor Deviation Reporting Form (
XLS, 74 KB)
Date: May 8, 2020
- Additional Guidance Regarding Reporting of Minor Deviations for Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 90 KB)
Date: March 27, 2020
- Interim Guidance for Patients on Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 84 KB)
Date: March 13, 2020
PLEASE NOTE: This is a reminder that infections occurring in subjects on clinical trials are considered adverse events, please see this additional guidance for reporting COVID-19 related adverse event.
Phase 0-I-II Prevention Clinical Trials Program Being Replaced with Grant Program
The National Cancer Institute is accepting applications for the Cancer Prevention Clinical Trials Network (CP-CTNet), a grant-funded network that will replace the contract-funded Phase 0-I-II Prevention Clinical Trials Program (Consortia). CP-CTNet will perform early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. For more information, List of Consortia Trials
PREVENT and DCP-funded Early Phase Clinical Projects’ Results Presented at AACR Virtual Annual Meetings I & II
NCI participated in the American Association for Cancer Research (AACR) Annual Meetings, held virtually on April 27 - 28, 2020 (Meeting I) and June 22 - 24, 2020 (Meeting II), including presenting the following research results from PREVENT and Early Phase Clinical Projects.
PREVENT and Consortia Project Results Presented at the AACR Annual Meeting 2019
NCI participated in the American Association for Cancer Research (AACR) Annual Meeting held March 29 - April 3, 2019 at Georgia World Congress Center in Atlanta, GA, including the presentation of research results from the latest PREVENT- and Consortia-supported projects.